Explore

Rapid Read Rapid Read
Medicare Policy Shift Delays AbbVie Drug’s Price Negotiation by Seven Years, Advocacy Group Claims

Medicare Policy Shift Delays AbbVie Drug’s Price Negotiation by Seven Years, Advocacy Group Claims

An advocacy group has highlighted a significant policy shift by Medicare that has resulted in a seven-year delay in the price negotiation eligibility for a major AbbVie drug. This change, which was not widely publicized, affects the timeframe in which the drug can be nominated for federally negotiated prices. The Inflation Reduction Act of 2022 had previously granted Medicare the ability to negotiate prices for select costly medications to make them more affordable. However, the recent policy shift extends the period before this particular drug can be negotiated, potentially impacting pharmaceutical spending and drug accessibility for millions of Americans. The advocacy group argues that this delay could lead to continued high prices, affecting Medicare's overall drug spending and out-of-pocket costs for beneficiaries.
Rapid Read Rapid Read
AARP Urges Congress to Strengthen Medicare's Ability to Negotiate Lower Prescription Drug Prices

AARP Urges Congress to Strengthen Medicare's Ability to Negotiate Lower Prescription Drug Prices

AARP is advocating for Congress to enhance Medicare's capacity to negotiate lower prescription drug prices, emphasizing the success of recent negotiations in saving Americans billions of dollars. The organization highlights the importance of making life-saving medications more affordable, as high drug prices can put essential treatments out of reach for many Americans. AARP's campaign calls on Congress to take further action to protect seniors from escalating drug costs by strengthening Medicare's negotiating power. The advocacy group argues that while progress has been made, more can be done to ensure that medications remain accessible and affordable for all.
Rapid Read Rapid Read
Kentucky Family Advocates for Organ Donation Reform After Medical Incident

Kentucky Family Advocates for Organ Donation Reform After Medical Incident

The family of TJ Hoover, a Kentucky man who regained consciousness before an organ removal surgery, is advocating for organ donation reform. Hoover was declared brain dead in 2021, but his unexpected recovery has prompted a federal investigation into the organ donation process. The Health Resources and Services Administration identified issues with medical assessments and family communication. The organ donation provider, Network for Hope, faces decertification due to persistent patient safety failures. Hoover's family seeks nationwide reform to ensure the safety of organ donation procedures.
Trendline Trendline
Immunovia Focuses on Medicare Submission and Partnerships to Boost Cancer Screening

Immunovia Focuses on Medicare Submission and Partnerships to Boost Cancer Screening

Immunovia Focuses on Medicare Submission and Partnerships to Boost Cancer Screening
Rapid Read Rapid Read
PALTmed Supports PURE Act to Improve Medicare Reimbursement for Portable Ultrasound

PALTmed Supports PURE Act to Improve Medicare Reimbursement for Portable Ultrasound

PALTmed has expressed strong support for the Portable Ultrasound Reimbursement Equity (PURE) Act, which aims to close a gap in Medicare policy by ensuring reimbursement for portable ultrasound transportation and set-up services. Introduced by a bipartisan group of lawmakers, including Reps. Beth Van Duyne, Brad Schneider, Mariannette Miller-Meeks, and Lori Trahan, along with Sens. John Cornyn and Maggie Hassan, the bill seeks to provide better access to timely diagnostics for patients, reducing the need for travel to medical facilities.
Trendline Trendline
Gainwell Technologies Seeks Senior Business Analyst for Healthcare Projects

Gainwell Technologies Seeks Senior Business Analyst for Healthcare Projects

Gainwell Technologies Seeks Senior Business Analyst for Healthcare Projects
Rapid Read Rapid Read
Bipartisan Senators Propose Reforms to 340B Drug Pricing Program

Bipartisan Senators Propose Reforms to 340B Drug Pricing Program

A bipartisan group of U.S. senators has introduced a bill to reform the 340B drug pricing program, which provides discounted drugs to healthcare providers serving low-income populations. The proposed legislation aims to establish new transparency and reporting requirements to ensure that the program's benefits reach patients rather than being retained by hospitals. The bill is supported by Senators Jerry Moran, Tammy Baldwin, Shelley Moore Capito, Tim Kaine, John Boozman, and John Hickenlooper. The reform efforts come amid ongoing debates between pharmaceutical companies and hospitals over the program's scope and implementation. While the bill seeks to preserve the program's critical benefits, some critics argue that it does not impose sufficient restrictions.
Trendline Trendline
Eli Lilly Reports 48% Revenue Surge in Q2 2026 Driven by Incretin Portfolio

Eli Lilly Reports 48% Revenue Surge in Q2 2026 Driven by Incretin Portfolio

Eli Lilly Reports 48% Revenue Surge in Q2 2026 Driven by Incretin Portfolio
Rapid Read Rapid Read
Senator Tim Sheehy Introduces Bill to Combat Foreign Drug Price Manipulation

Senator Tim Sheehy Introduces Bill to Combat Foreign Drug Price Manipulation

Senator Tim Sheehy has introduced the 'Use Sovereignty to Reduce Rx Act' (USTRx Act) to address foreign drug price manipulation, particularly targeting Germany's pricing practices. The bill aims to establish a new pharmaceutical trade negotiator within the U.S. Trade Representative's office and requires annual reports on foreign drug pricing abuses. The legislation seeks to ensure that high-income countries do not use price controls that disadvantage American innovation. Representative Jodey Arrington is leading companion legislation in the House. The bill reflects growing concerns about foreign governments benefiting from American pharmaceutical research while imposing price controls.
Trendline Trendline
CVS Health Faces Challenges from 340B and PBM Reforms Despite Strong Earnings

CVS Health Faces Challenges from 340B and PBM Reforms Despite Strong Earnings

CVS Health Faces Challenges from 340B and PBM Reforms Despite Strong Earnings
Rapid Read Rapid Read
CBO Revises Cost Estimates of IRA Drug Provisions, Revealing Increased Taxpayer Burden

CBO Revises Cost Estimates of IRA Drug Provisions, Revealing Increased Taxpayer Burden

The Congressional Budget Office (CBO) has revised its cost estimates for the drug pricing provisions in the Inflation Reduction Act (IRA), revealing that instead of saving $129 billion, these provisions have cost $700 billion. This revision follows a request from House committee chairmen, including Jodey Arrington, to explore the budgetary effects of the IRA on Medicare Part D. The CBO's findings indicate that the provisions have led to increased costs for taxpayers and reduced the number of available drug plans. Critics argue that the price controls have not delivered the promised savings and have instead increased healthcare costs.
Rapid Read Rapid Read
Kevin Sexton Appointed to Lead Maryland's Health Services Cost Review Commission

Kevin Sexton Appointed to Lead Maryland's Health Services Cost Review Commission

Kevin Sexton, former CEO of Holy Cross Health, has been appointed to chair Maryland's Health Services Cost Review Commission (HSCRC). This appointment comes as the commission prepares to implement a new rate-setting model that will limit the state's authority to regulate hospital prices. The new model, developed over two years of negotiations, aims to improve healthcare efficiency and community health. Sexton's appointment is seen as a strategic move to guide the commission through this transition, leveraging his extensive experience in healthcare management.